table 2
Summary of the process of developing guideline
recommendations
Guideline Scope
ESMO (European Society for
Medical Oncology) • Covers IV and oral chemotherapy
• Classification of emesis
• Prevention of acute emesis for high
MASCC (Multinational Association
of Supportive Care in Cancer) and moderate emetic chemotherapy
• Prevention of delayed emesis
for high and moderate emetic
chemotherapy
• Prevention of emesis for minimal
and low emetic chemotherapy
• Refractory emesis
• Rescue antiemetic therapy
• Multi-day chemotherapy
• High-dose chemotherapy
• Anticipatory emesis
• Radiotherapy-induced emesis
• Paediatric patients
• Nausea and vomiting in advanced
cancers
ASCO (American Society of Clinical
Oncology) • Covers IV and oral chemotherapy
• Classification of emesis
• Prevention of CINV for high and
moderate emetogenic chemotherapy
• Prevention of CINV for low and
minimally emetogenic chemotherapy
• Combination chemotherapy
• Adjunctive drugs
• Complementary therapy
• Paediatric patients
• Multi-day chemotherapy
• High-dose chemotherapy
• Emesis despite prophylaxis
20 | 2018 | hospitalpharmacyeurope.com